Accession Number : ADA335055
Title : Improved 5-Fluorouracil Chemotherapy in Breast Cancer Patients by Monitoring Dihydropyrimidine Dehydrogenase Activity
Descriptive Note : Final rept 15 Aug 94-14 Aug 97
Corporate Author : ALABAMA UNIV IN BIRMINGHAM
Personal Author(s) : Lu, Zhihong
PDF Url : ADA335055
Report Date : SEP 1997
Pagination or Media Count : 34
Abstract : Dihydropyrimidine Dehydrogenase (DPD) is the initial, rate-limiting enzyme in catabolism of 5- fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The purpose of this project is to improve 5-FU-based chemotherapy by monitoring DPD.
Descriptors : *CHEMOTHERAPEUTIC AGENTS, *BREAST CANCER, PATIENTS, CATABOLISM, DEHYDROGENASES.
Subject Categories : Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE